Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexane SCHEMBL9763562 | 0.82 | TDP1 (0.57) | TDP1MEN1FAAHMAPK1KMT2A | |
| Hexane SCHEMBL9763768 | 0.79 | TDP1 (0.53) | TDP1MEN1FAAHMAPK1KMT2A | |
| Heptane SCHEMBL17938082 | 0.79 | TSHR (0.53) | TDP1MEN1FAAHMAPK1KMT2A | |
| Heptane SCHEMBL29087108 | 0.77 | TSHR (0.50) | TDP1MEN1FAAHMAPK1KMT2A | |
| Heptane SCHEMBL2515743 | 0.77 | TSHR (0.50) | TDP1MEN1FAAHMAPK1KMT2A | |
| SCHEMBL449933 | 0.72 | TSHR (0.55) | TDP1MEN1FAAHMAPK1KMT2A | |
| Butylamine SCHEMBL2810676 | 0.72 | DNM1 (0.48) | TDP1MEN1KMT2ATSHROPRM1 | |
| SCHEMBL1317865 | 0.72 | TDP1 (0.44) | TDP1MEN1FAAHMAPK1KMT2A | |
| SCHEMBL9316767 | 0.72 | TDP1 (0.44) | TDP1MEN1FAAHMAPK1KMT2A | |
| Isobutanol SCHEMBL1992818 | 0.72 | TSHR (0.50) | TDP1MEN1MAPK1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304531-B2 | Process for the preparation of an (RP)-8-substituted cAMPS | SOLVELL AS (NO) | 2012-11-06 | — | — | US | disclosed |
| US-20100137237-A1 | PROCESS FOR THE PREPARATION OF AN (RP)-8-SUBSTITUTED CAMPS | LAURAS AS (NO) | 2010-06-03 | — | — | US | disclosed |
| EP-2081947-A2 | PROCESS FOR THE PREPARATION OF AN (RP)-8-SUBSTITUTED CAMPS | Lauras AS (NO) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008032103-A2 | PROCESS FOR THE PREPARATION OF AN (RP)-8-SUBSTITUTED CAMPS | LAURAS AS (NO) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137237-A1 | PROCESS FOR THE PREPARATION OF AN (RP)-8-SUBSTITUTED CAMPS | AMPD3, ATIC, PDE8A | TDP1 1481/4885MEN1 2237/4885FAAH 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.